A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice

详细信息    查看全文

• 作者：Pablo F. Cé ; spedes^a ; ¹ ; Emma Rey-Jurado^a ; ¹ ; Janyra A. Espinoza^a ; Claudia A. Rivera^a ; Gisela Canedo-Marroquí ; n^a ; Susan M. Bueno^a ; Alexis M. Kalergis^a ; ^b ; ^c ; ^{akalergis@bio.puc.cl}
• 关键词：BAL ; bronchoalveolar lavage ; BCG ; Bacillus Calmette et Guerin ; CFUs ; colony-forming units ; cGMP ; current Good Manufacturing Practices ; hRSV ; human respiratory syncytial virus ; FI-hRSV ; formalin-inactivated hRSV ; HI-hRSV ; heat-inactivated hRSV ; FACS ; fluorescence activated cell sorting
• 刊名：Vaccine
• 出版年：2017
• 出版时间：1 February 2017
• 年：2017
• 卷：35
• 期：5
• 页码：757-766
• 全文大小：2677 K
• 卷排序：35

文摘

A single dose of 3 × 105 CFUs of rBCG-N-hRSV cGMP elicits T-cell memory against hRSV. rBCG-N-hRSV cGMP elicits a strong antiviral TH1/TH17 T-cell repertoire. Vaccination prevents viral pneumonia and CNS-alterations associated with hRSV. rBCG-N-hRSV cGMP elicits a strong anti-mycobacterial TH1/TH17 T-cell repertoire. Immunity to hRSV and Mtb antigens develops without observable adverse effects.